Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Other

4

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

C-C chemokine receptor type 1

4

C-C chemokine receptor type 2

4

C-C chemokine receptor type 3

4

C-C chemokine receptor type 5

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Not Provided

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

4

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Asthma

2

HIV-1 infection

2

Multiple sclerosis

2

Rheumatoid arthritis

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Banyu Pharmaceutical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

4

FDA UNII

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

J-113863 CATION, TRANS-

Y99524800Z

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

C-C chemokine receptor type 1

C-C chemokine receptor type 3

C-C chemokine receptor type 2

C-C chemokine receptor type 5

Conditions:

HIV-1 infection

UCB35625 is a potential inhibitor of chemokine/eosinophil interactions. UCB35625 is a trans-isomer of a compound J113863, which was originally identified by scientists at Banyu Pharmaceutical Company as a candidate small molecule chemokine receptor a...

ntagonist. UCB35625 initially identified as CCR1 and CCR3 antagonists also bind to CCR2 and CCR5 and act as full agonist, partial agonist or antagonist according to the nature of the receptor and the signaling pathway investigated. UCB35625 shows promise as a lead compound for the design of future therapeutics, which may be of use in the treatment of allergic inflammatory diseases such as asthma and also the blockade of viral entry by HIV strains that utilize CCR3.

J-113863 CATION, CIS-

E449119QPL

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

C-C chemokine receptor type 1

C-C chemokine receptor type 3

C-C chemokine receptor type 5

C-C chemokine receptor type 2

Conditions:

Rheumatoid arthritis

Multiple sclerosis

J 113863 is a potent and high selective CKR-1 (CCR1) and CKR-3 (CCR3) chemokine receptor antagonist, which is also behaved as a full agonist of CCR2 and as a very partial agonist of CCR5. This compound was investigated for the treatment of multiple s...

clerosis and rheumatoid arthritis, but the status of these studies are not known.

J-113863, CIS-

H942HGF14D

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

C-C chemokine receptor type 1

C-C chemokine receptor type 3

C-C chemokine receptor type 5

C-C chemokine receptor type 2

Conditions:

Rheumatoid arthritis

Multiple sclerosis

J 113863 is a potent and high selective CKR-1 (CCR1) and CKR-3 (CCR3) chemokine receptor antagonist, which is also behaved as a full agonist of CCR2 and as a very partial agonist of CCR5. This compound was investigated for the treatment of multiple s...

clerosis and rheumatoid arthritis, but the status of these studies are not known.

J-113863, TRANS-

HD099HOT7H

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

C-C chemokine receptor type 1

C-C chemokine receptor type 3

C-C chemokine receptor type 2

C-C chemokine receptor type 5

Conditions:

HIV-1 infection

UCB35625 is a potential inhibitor of chemokine/eosinophil interactions. UCB35625 is a trans-isomer of a compound J113863, which was originally identified by scientists at Banyu Pharmaceutical Company as a candidate small molecule chemokine receptor a...

ntagonist. UCB35625 initially identified as CCR1 and CCR3 antagonists also bind to CCR2 and CCR5 and act as full agonist, partial agonist or antagonist according to the nature of the receptor and the signaling pathway investigated. UCB35625 shows promise as a lead compound for the design of future therapeutics, which may be of use in the treatment of allergic inflammatory diseases such as asthma and also the blockade of viral entry by HIV strains that utilize CCR3.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1